8-K: Vivos Therapeutics Reports 16% Revenue Growth for 2025

Vivos Therapeutics reported $17.5 million in 2025 revenue, driven by sleep testing services and the acquisition of The Sleep Center of Nevada.

Summary

• Full-year 2025 revenue reached $17.5 million, a 16% increase from $15.0 million in 2024.
• Gross profit rose 17% to $10.5 million, maintaining a steady 60% gross margin.
• Operating loss widened to $19.9 million in 2025, compared to $11.2 million in 2024, due to integration costs and strategic investments.
• Cash and cash equivalents stood at $2.0 million as of December 31, 2025, supplemented by $6.8 million in post-year-end financing.
• The company is shifting its business model from training dentists to acquiring and partnering with sleep specialty medical providers.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral report; while revenue growth is positive, the widening operating losses and negative stockholders' equity highlight significant financial strain and execution risk.

Positives

• 16% year-over-year revenue growth.
• 17% increase in gross profit.
• Successful integration of The Sleep Center of Nevada assets.
• Maintained a consistent 60% gross margin despite significant operational changes.
• Secured $6.8 million in additional financing post-year-end to bolster liquidity.

Negatives

• Operating loss nearly doubled to $19.9 million from $11.2 million in 2024.
• Net loss attributable to stockholders increased to $21.17 million.
• Cash position dropped to $2.0 million at year-end from $6.26 million in the prior year.
• Stockholders' equity turned negative, ending at a deficit of $1.55 million.

Risks

• Potential inability to secure additional financing on reasonable terms.
• Risk of failing to maintain Nasdaq listing requirements due to stockholders' equity deficiency.
• Uncertainty regarding the successful implementation of the new revenue and marketing strategies.
• Regulatory scrutiny and potential adverse publicity in the sleep apnea treatment sector.
• Patient outcomes may not meet expectations, impacting adoption rates.

Future Outlook

Management aims to achieve cash flow positive operations by the end of 2026 through cost-savings initiatives, the new acquisition-based business model, and improved contribution margins.

Management Comments

• 2025 was a pivotal year for Vivos.
• We grew full-year revenue by 16% and maintained gross margin despite significant investment.
• We believe these actions position Vivos to drive higher top-line growth and a clear path toward cash flow positive operations by the end of this year.

Industry Context

StockSavvy.ai notes that Vivos is pivoting away from the 'dentist-training' model toward a direct-provider acquisition strategy, mirroring a broader industry trend where medical device companies seek to control the patient care pathway to improve reimbursement and clinical outcomes.

Comparison to Industry Standards

• The 60% gross margin is competitive for medical device companies, though the high operating expense ratio relative to revenue indicates significant scaling challenges.
• The shift toward direct clinical ownership is a strategy often seen in specialized healthcare services to capture higher margins compared to pure-play device manufacturing.

Stakeholder Impact

• Shareholders face dilution risks and concerns regarding the company's ability to maintain Nasdaq listing standards.
• Creditors may be concerned by the negative equity position and reliance on external financing.

Next Steps

• Host investor conference call on April 15, 2026.
• Execute cost-savings initiatives to reach cash flow positive status by year-end 2026.

Key Dates

Recommendation

The company is in a high-risk transition phase. While revenue is growing, the burn rate and negative equity position necessitate a cautious 'hold' until the company demonstrates a clear, sustained path to cash flow positivity.

Keywords

Vivos Therapeutics, VVOS, Obstructive Sleep Apnea, Sleep Medicine, Medical Devices, Healthcare Services, Financial Results